Radiopharm Theranostics Ltd
RAD
Company Profile
Business description
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Contact
62 Lygon Street
Suite 1, Level 3, Carlton South
MelbourneVIC3053
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
14
Stocks News & Analysis
stocks
ASX gold miner under pressure to sell by activist investor
Activist investor presses gold miner on selling to larger players.
stocks
Ask the Analyst: Will Amcor lose its dividend aristocrat status?
When consistency becomes constraint.
stocks
Chart of the Week: We see opportunity in this beaten down industrial player
The market sees risks and are discounting the shares excessively.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,916.90 | 58.60 | -0.65% |
| CAC 40 | 8,203.73 | 53.31 | 0.65% |
| DAX 40 | 24,927.49 | 131.55 | 0.53% |
| Dow JONES (US) | 50,687.07 | 620.72 | -1.21% |
| FTSE 100 | 10,347.39 | 15.09 | 0.15% |
| HKSE | 25,283.61 | 349.60 | -1.36% |
| NASDAQ | 26,853.98 | 239.92 | -0.89% |
| Nikkei 225 | 67,470.69 | 931.45 | -1.36% |
| NZX 50 Index | 13,101.61 | 13.47 | -0.10% |
| S&P 500 | 7,553.68 | 56.10 | -0.74% |
| S&P/ASX 200 | 8,686.10 | 59.50 | -0.68% |
| SSE Composite Index | 4,057.78 | 26.19 | -0.64% |